News | August 06, 2012

Report Indicates Fate of Brachytherapy May Rest on Financial Benefits

August 6, 2012 — Brachytherapy offers an effective and relatively inexpensive method of treating internal cancers, and its popularity in the future will likely rely on its financial status, according to a new report by GlobalData.

The new report, Brachytherapy Devices - Global Opportunity Assessment, Competitive Landscape and Market Forecasts to 2018, suggests that the growing cost of cancer treatment has intensified focus on the cost-effectiveness of treatment approaches, and brachytherapy is perceived to be the best option.

Assessment of the costs and benefits of new and existing cancer treatment methods are essential for clinicians, payers and healthcare policymakers. Lifetime treatment costs for brachytherapy have been found to be nearly $3,000 lower than costs for radical prostatectomy in the treatment of low-risk prostate cancer, making it a high-value alternative. Data from U.S. patients newly diagnosed with prostate cancer over five and a half years revealed that brachytherapy was among the most cost-effective options, totaling a comparatively low $35,143.

The need for fewer treatments best serves patients who do not have local access to radiation treatment, cutting out lengthy journeys to an oncology center and representing significant cost savings for patients, as transportation costs constitute out-of-pocket expenses. Brachytherapy also saves money for healthcare systems, as lifetime treatment through brachytherapy costs substantially less than radical prostatectomy and intensity-modulated radiation therapy (IMRT).

Moreover, temporary brachytherapy is gaining popularity among both physicians and patients due to its ease of use as an outpatient procedure. Treatment is also shorter, and has a lower risk of serious adverse effects, making it altogether more likely for patients to conform to treatment schedules and refrain from wasting appointment times.

However, Medicare reimbursement cuts threaten the growth of the brachytherapy devices market in the United States, potentially removing brachytherapy from a huge portion of the global cancer patient population. The 2012 final Medicare Physician Fee Schedule (MPFS) saw Centers for Medicare and Medicaid Services (CMS) finalize proposals reducing Medicare payment rates for physicians by 27.4 percent for services in 2012. Earlier in 2010, the CMS under the MPFS-proposed rule implemented reimbursement cuts of 19 percent for radiation oncology. Based on these changes, it is estimated that radiation oncology, including brachytherapy, will experience an impact of negative 6 percent in 2012 and negative 10 percent in 2013.

For more information: www.globaldata.com

Related Content

California US Oncology Network Centers Adopt Xoft Electronic Brachytherapy System for Early-Stage Non-Melanoma Skin Cancer
News | Brachytherapy Systems | January 02, 2018
iCAD Inc. announced that its Xoft Axxent Electronic Brachytherapy (eBx) System is now available at two California-based...
Intraoperative Radiotherapy Provides Lifetime Cost Savings, Health Benefits for Early-Stage Breast Cancer Treatment
News | Brachytherapy Systems, Women's Healthcare | December 19, 2017
iCAD Inc. announced the results of a landmark study that showed the benefits of adjunct intraoperative radiation...
Videos | Radiation Therapy | November 15, 2017
Chris Toth, president, global commercial and field operations for Varian, takes a tour of Varian’s new product introd
Sam Hancock, Ph.D.

Sam Hancock, Ph.D.

Sponsored Content | Case Study | Radiation Oncology | November 06, 2017
In establishing the new Southeast Cancer Center (Cape Girardeau, Mo.), clinic officials not only had the opportunity to...
Proton therapy doesn’t get as near to the heart and other internal organs as X-ray therapy does. (Image courtesy of Provision Cares Proton Therapy Center.)

Proton therapy doesn’t get as near to the heart and other internal organs as X-ray therapy does. (Image courtesy of Provision Cares Proton Therapy Center.)

Feature | Proton Therapy | November 06, 2017 | By Larisa Brass, MPH
Thirty-three. Twenty-nine. Sixty-four. These are the ages of the breast cancer patients who have walked through the...
Videos | Women's Health | October 23, 2017
William Hall, M.D., radiation oncologist in the Department of Radiation Oncology at PeaceHealth St. Joseph Medical...
Xstrahl Photoelectric Therapy System Receives FDA 510(k) Clearance
Technology | Radiation Therapy | October 20, 2017
Xstrahl announced that its Photoelectric Therapy System has received U.S. Food and Drug Administration (FDA) 510(k)...
Pancreatic Cancer Outcome Highlights via On-table Adaptive MR-guided Radiation Therapy, MRI guided RT.
Sponsored Content | Webinar | Radiation Therapy | October 13, 2017
The webinar "Pancreatic Cancer Outcome Highlights via On-table Adaptive MR-guided Radiation" was presented by Parag P
News | Brachytherapy Systems | October 05, 2017
External researchers presented new clinical data supporting the use of iCAD’s Xoft Axxent Electronic Brachytherapy (eBx...
International Trial Confirms Safety, Effectiveness of High-Dose Brachytherapy Plus Pelvic Radiation for Cervical Cancer
News | Brachytherapy Systems, Women's Healthcare | October 04, 2017
Findings from a new multicenter, international clinical trial confirm the effectiveness of high-dose brachytherapy or...
Overlay Init